CCR2 and focal segmental glomerulosclerosis: Similarly, clinical trials involving CCX140-B, a CCR2 antagonist, have reported decreased proteinuria in patients with DKD and focal segmental glomerulosclerosis (FSGS), suggesting a potential renoprotective effect (126, 127).